Day 1 - Friday, 25 September 2026,
8am to 5.30pm

Time

Title

Speakers

7.30am to 7.55am

Registration

7.55am to 8am

Day 1 Opening Remarks

Session 1 – Moderators: Dr. Ashraf Awadelkarim and Dr. Nazeeha AlHayki

8am to 8.15am

Melanoma and Skin Cancers (Abstract LBA9503): Darovasertib in combination with crizotinib versus investigator’s choice as first-line treatment for patients with HLA-A2–negative metastatic uveal melanoma: Results

from the phase 2/3 OptimUM-02 study.

Dr. Mohamed Aboagla

Specialist, Oncologist, NCCCR

8.15am to 8.30am

Melanoma and Skin Cancers (Abstract LBA9505): Updated Outcomes from STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III

Trial: ECOG-ACRIN EA6174.

Dr. Ashraf Awadelkarim Associate Consultant Medical Oncologist, NCCCR

8.30am to 8.45am

Sarcoma (Abstract 11506): RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.

Dr. Abdulaziz Al-Jassim Consultant Medical Oncologist, Hematology & Medical Oncology,

Cancer Control Center - Kuwait

8.45am to 9am

Sarcoma (Abstract LBA2): SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in

patients with advanced dedifferentiated liposarcoma.

Dr. Mutie Ullah Ahmed

Clinical Fellow, Oncologist, NCCCR

9am to 9.15am

PANEL DISCUSSION

9.15am to 9.30am

Coffee Break

Session 2 – Moderators: Dr. Mohammed Faisal Eltagalawi and Dr. Abdulrehman Zar Gul

9.30am to 9.45am

Head and Neck Cancer (Abstract 6008): Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results

from the phase 1b/2 OrigAMI-4 study.

Dr. Khaled Wagdi Sadek

Clinical Fellow, Medical Oncologist, NCCCR

9.45am to 10am

Head and Neck Cancer (Abstract 6004): Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group,

non-inferiority, randomized, phase 3 trial.

Dr. Abdulrehman Zar Gul

Senior Consultant Medical Oncologist, NCCCR

10am to 10.15am

Head and Neck Cancer (Abstract 6002): Metronomic adjuvant chemotherapy (MACE) in locally advanced oral cavity squamous cell carcinoma post-surgery and adjuvant treatment (MACE postop): A phase III randomized

controlled trial.

Dr. Aladdin Kanbour Consultant Medical Oncologist, NCCCR

10.15am to 10.30am

Head and Neck Cancer (Abstract 6000): Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST; CTRI/2017/07/009114).

Dr. Venkada Manickam Specialist Radiation Oncologist, NCCCR

10.30am to 10.45am

Symptom Science and Palliative Care (Abstract 12004): YOCAS yoga, mood disturbance, and insomnia: A URCC NCORP RB nationwide, phase III, randomized, controlled trial with cancer survivors.

Dr. Mohammed Faisal Eltagalawi Development Researcher, Professional Development and Research Department, Qatar Cancer

Society

10.45am to 11am

PANEL DISCUSSION

11am to 1pm

Friday Prayer & Lunch Break

Session 3 – Moderators: Dr. Salha Bujassoum & Dr. Nabeeha Karadawi

1pm to 1.15pm

Breast Cancer—Metastatic (Abstract 1005): Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.

Dr. Francois Calaud Senior Consultant Medical Oncologist, NCCCR

1.15pm to 1.30pm

Breast Cancer—Local/Regional/Adjuvant (Abstract 500): First results from the OPTIMA phase III randomized non- inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.

Dr. Aydah Al Awadhi Consultant Medical Oncologist and Chair of the Hematology & Oncology Division at Sheikh Shakhbout Medical City in Abu Dhabi, UAE

1.30pm to 1.45pm

Breast Cancer—Metastatic (Abstract LBA1000): Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT- 04 study of participants (pts) with previously untreated PD- L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus

pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.

Dr. Mufid El Mistiri Senior Consultant Medical Oncologist, NCCCR

1.45pm to 2pm

Breast Cancer—Metastatic (Abstract LBA1006):

Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET)

+ PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2–

LA/mBC): Primary analysis of the phase III persevERA BC trial.

Dr. Ahlam Yousif

Consultant Medical Oncologist, NCCCR

2pm to 2.15pm

Breast Cancer—Metastatic (Abstract LBA1007): First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the Phase III

SERENA-6 trial.

Dr. Mohammed Gaber Associate Consultant, Medical Oncologist, NCCCR

2.15pm to 2.30pm

PANEL DISCUSSION

Session 4 – Moderators: Dr. Mufid El Mistiri and Dr. Francois Calaud

2.30pm to 2.45pm

Prevention, Risk Reduction & Genetics (Abstract 10515): Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status.

Dr. Salha Bujassoum

Senior Consultant Medical Oncologist, NCCCR

2.45pm to 3pm

Breast Cancer—Metastatic (Abstract 1012): Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+

unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.

Dr. Nabeeha Karadawi Consultant Medical Oncologist, NCCCR

3pm to 3.15pm

Breast Cancer—Metastatic (Abstract LBA1008): A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in

HR+/HER2−/PIK3CA-mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2).

Dr. Shaza Bek

Associate Consultant, Medical Oncologist, NCCCR

3.15pm to 3.30pm

Prevention, Risk Reduction & Genetics (Abstract LBA100): NHS-Galleri: Primary results from a randomized controlled trial to assess the clinical

utility of a multi-cancer early detection (MCED) test in population screening.

Dr. Shaima Abdelrahim Specialist, Medical Oncologist, NCCCR

3.30pm to 3.45pm

PANEL DISCUSSION

3.45pm to 4pm

Prayer & Coffee Break

Session 5 – Moderators: Dr. Ikram Burney, Dr. Hind El Malik and Dr. Afaf Al-Ansari

4pm to 4.15pm

Gynecologic Cancer (Abstract 5517): Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.

Dr. Cicy Mary Jacob

Consultant Medical Oncologist, NCCCR

4.15pm to 4.30pm

Gynecologic Cancer (Abstract 5505): CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer.

Dr. Ikram Burney

Senior Consultant, Medical Oncology at Sultan Qaboos, Oman

4.30pm to 4.45pm

Gynecologic Cancer (Abstract 5506): A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).

Dr. Hind El Malik

Senior Consultant Medical Oncologist,

NCCCR

4.45pm to 4.55pm

PANELDISCUSSION

4.55pm to 5.30pm

Day 1 Closing Remarks

Celebrating Our Valued Members

- SPC, Organizing & Poster committees

Celebrating Our Valued Partners

- Sponsors honoring

Conference Group Photo

Dr. Mohammed Ussama Al- Homsi

Conference Chairman

Senior Consultant, Medical Oncology, Ministry of Public Health (MoPH)

Dr. Anas Hamad

Chairman of Organizing Committee Deputy Chief of Drug Supply, HMC​​